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Abdominal Aortic Aneurysm e To Screen or Not to Screen
D. Bergqvist,* M. Bjo¨rck and A. Wanhainen
Department of Surgical Sciences, Section of Surgery, Uppsala University Hospital, Uppsala, Sweden
With the ten WHO criteria for a screening program to be started, screening for abdominal aortic aneurysm is analyzed.
Most of the criteria are fulfilled concerning the 65-year old male population, whereas concerning females we need more
knowledge. Still the aneurysmal diameter is the most important factor to select patients for treatment meaning that
many aneurysms are treated where rupture should never have occurred. Research projects giving more information on
pathophysiological processes behind expansion and rupture should have priority.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The World Health Organization (WHO) has defined
screening as a medical investigation which does not
arise from a patient’s request for advice for specific
symptoms or complaints and moreover indicated
the important criteria for a screening process to be un-
dertaken (Table 1)1 The intuitively most important cri-
terion is that the population or parts of it can harbour
asymptomatic diseases, which nonetheless are severe
and perhaps also life-threatening, if not treated. Ab-
dominal aortic aneurysm (AAA) is such a disease.
In 1990 we used the WHO criteria to analyze AAA
from a screening perspective.2 Since then our knowl-
edge on AAA has increased, and results from popula-
tion based screening studies have been reported.3e8
Yet there is a debate whether or not and in which sit-
uations screening may be indicated.9
The purpose of this paper is to discuss how con-
temporary knowledge about AAA stands in relation
to the WHO criteria recommended to introduce
screening1,2,10,11 and to address critical areas where
the knowledge is still insufficient.
*Corresponding author. D. Bergqvist, Professor of Vascular Surgery,
Department of Surgical Sciences, Section of Surgery, Uppsala Uni-
versity Hospital, SE-751 85 Uppsala, Sweden.
E-mail address: david.bergqvist@surgsci.uu.se1078–5884/000013+ 06 $32.00/0  2007 European Society for Vascu(1) The disease should be an important
health problem
Roughly 1% of all deaths are caused by ruptured
AAA, and in elderly men it may be as high as 2%.12
It is reasonable to assume that the magnitude of the
health problem is underestimated by the fact that the
autopsy-rate is very low in most countries, especially
among elderly. In 2003, 14% of those who died in Swe-
den were examined post-mortem, and only 8% among
those above 75 years (Do¨dsorsaker 2003).13 The in-
crease of the age-standardized incidence in the well
studied population of the city of Malmo¨ observed dur-
ing 1971e198614 has continued to 2004.15
Male sex and high age are the most important risk
factors for AAA,16 and several studies have shown
that screeningmen above 65 years significantly reduces
AAA related mortality.4e6 A suitable age in the male
population above which the prevalence is high enough
to consider screening seems to be somewhere around
65 years.17,18 However, the optimal age has not yet
been established in clinical trials.
Women are generally not considered a suitable tar-
get population for AAA screening. The main reason is
the low prevalence of AAA,19 but also the develop-
ment of the disease later in life among women.14
However, other aspects of the disease, such as the
higher rupture rate, indicate that AAA in women
may indeed be more severe than in men.20lar Surgery. Published by Elsevier Ltd. All rights reserved.
14 D. Bergqvist et al.One way to increase the yield in a screening situa-
tion is to identify high risk groups. Patients with pop-
liteal aneurysms21 and first degree male relatives to
patients with AAA22 are established high risk groups,
where screening is uncontroversial. Other high risk
groups such as smokers19 or patients with atheroscle-
rotic manifestations23e25 may, however, also be suit-
able target population for AAA screening.
(2) A generally acceptable method of treatment must be
available and (3) the policy for treatment must be clear
This is a truism or screening would otherwise be
meaningless. In the case of AAA two options are pos-
sible: Open repair (OR) and endovascular repair
(EVAR). Both are effective and this is not the place
to discuss pros and cons of the two. Suffice to say,
that today both have been extensively used, although
the endovascular technique still is in its development
and much more has to be learnt about complications,
follow-up routines and need for re-interventions. Ac-
cording to the Swedish Vascular Registry (Swedvasc)
36% of all elective repairs in 2005 was done with en-
dovascular technique and the 30 day mortality was
2.9% for both OR and EVAR.26 Two studies have
shown the safety of surveillance until a diameter of
the AAA reaches 5.5 cm among male patients.27,28
Although questioned by some,29,30 most surgeons
agree that in selected cases an AAA diameter of
5.0e5.5 cm generally justifies elective repair.27,28 How-
ever, an individual approach is recommended.
For older patients and patients with important co-
morbidity the threshold diameter is greater, and
12e25% of the patients are considered unfit for
surgery.27 The specific surgical indication for particular
Table 1. The WHO ten criteria for screening
1. The disease should be an important health problem
2. A generally acceptable method of treatment must be available
3. The policy for treatment must be clear
4. Provision for diagnosis and treatment must be available
5. The disease must have a detectable latent stage
6. A suitable screening method must be available
7. The screening method must be accepted by the target population
8. The natural course of the disease must be known
9. The program must be cost-effective
10. The treatment of the disease should favour the prognosis of the
patients
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AAA and women) has not been evaluated sufficiently.
Therapeutic strategies directed at reducing expan-
sion are scarce. Propranolol was shown to have no ef-
fect on expansion in a randomized trial,31 and none of
the statin trials have reported on aortic diameters.
Doxycycline, an effective but non-selective MMP-
inhibitor, is currently under evaluation, and selective
MMP inhibitors are being developed.32
Although we lack a specific treatment to inhibit ex-
pansion and reduce the risk of rupture, smoking ces-
sation in patients with screening detected AAAwould
improve the prognosis of the patient substantially, in-
cluding the risk of expansion and rupture. Consider-
ing the high prevalence of atherosclerosis and
smoking among AAA patients screening program
for AAA should consider to include secondary pre-
vention measures.
(4) Provision for diagnosis and treatment
must be available
When a population-based screening program is im-
plemented an increasing amount of follow-up duplex
scans will have to be organized. When a large propor-
tion of patients undergo EVAR, the surveillance pro-
gram after EVAR is increasingly demanding.
Screening elderly men has reduced the demand of
resources to operate ruptured AAA by 50%. On the
other hand, the number of elective repairs increased
by 100e400%.4e6 The net effect is a significant and re-
source demanding increase in operations for AAA.
The screening strategy affects the demand of resour-
ces. It is easier to handle the low increase in demands
of therapeutic and diagnostic resources if, for instance,
men are screened once at the age of 65, than if greater
cohort are screened at the start of the screening
program.16,17,33
(5) The disease must have a detectable
latent stage
This is certainly true for AAA where several years of
expansion precede the stage, when there is a risk of
rupture. Two large randomised trials have shown
the safety of ‘‘watchful waiting’’ for AAA less than
5.5 cm.27,28 This conclusion was recently confirmed
in the final 12-year follow-up analysis of surgery ver-
sus surveillance in the UK Small Aneurysmal trial.34
Adapting a screening program in a population will
lead to detection of a certain number of small AAA.
In fact most screening detected AAA are small, 70%
being less than 4.0 cm,19 and 2/3 of all screening
15AAA Screeningdetected AAA never reach the size of elective repair
or rupture. This will induce the need to inform
‘‘healthy persons’’ that they harbour a potentially
dangerous disease, which does not need treatment
at present, and that they will have to be followed
with regular ultrasonography.
(6) A suitable screening method must be available
and (7) the screening method must be accepted
by the target population
The screening method should not only show a high
diagnostic accuracy but should also be inexpensive
and safe. Ultrasonography (US) is a non-invasive
test that fulfils these criteria. Although visibility may
be affected by obesity and bowel gas, the reported vis-
ibility of infrarenal aorta varies between 96e100%.35
US has the ability to compensate for vessel angula-
tion, and is less sensitive to aortic angulation than ax-
ial computed tomography.36 US is moreover very
rapid with the potential for a single operator to screen
up to fifteen persons per hour. US has been used in
several population-based screening programs with at-
tendance rates above 75%, in one as high as 91%.35
The technique is, however, subject to both inter- and
intraobserver variability, and variations of 0.5 cm or
more are not uncommon.37
(8) The natural course of the disease must be known
The natural course of AAA includes aspects on the an-
eurysm as well as on the patient carrying the disease.
Natural history studies are rather old as at present in-
vasive treatment is used, although indications may
vary. Information may also be extrapolated from stud-
ies of small AAA and from studies of patients unfit for
surgery. In summary, the natural course of AAA is to
gradually expand and eventually to rupture.
The average expansion pattern is exponential
rather than linear, estimated to about 10% annually.38
However, individual variations are considerable. It is
also notable that about 1/3 of the very small AAAs
(<3.5 cm), do not expand at all.39e42 In addition to
the initial diameter, rapid expansion is associated
with age, smoking and hypertension.40,43e45 Unfortu-
nately the pathophysiological mechanism responsible
for aneurysm expansion is not known, and besides
smoking cessation and maybe treatment of hyperten-
sion, no specific therapy to prevent or reduce expan-
sion exists today.
Less than 20% of all AAAs eventually rupture.14 The
risk of rupture is in proportion to the aneurysm size.
Small AAAs, less than 5.0 cm, have a very low rupturerate, whereas the rate of rupture is approximately
5e10% per year for AAAs between 5.0 to 6.0 cm and
more than 10% for AAAs larger than 6.0 mm.46 At
a size of 5e5.5 cm in diameter most surgeons therefore
agree that OR or EVAR is indicated, in the absence of
contraindications. In addition to size, female sex, a pos-
itive family history, smoking, hypertension and chronic
obstructive pulmonary disease are associated with an
increased risk of rupture, although much knowledge
is still lacking. The expansion rate and the ratio of in-
frarenal to suprarenal diameters aswell as local factors,
such as localised dilatations (‘‘blebs’’), intraluminal
thrombosis, and tenderness, may also affect the risk
of rupture.44,47,48
Due to co-morbidities patients with AAA have an
increased overall mortality, unrelated to the AAA,
compared to a general aged-matched population.49
Overall, the relative 5 year survival is estimated to
90% after successful AAA repair.50 The specific life ex-
pectancy of patients with AAAs, depending on their
gender and age, and if they are operated on for large
AAAs, or small AAAs under surveillance, has not
been sufficiently studied.
(9) The program must be cost-effective
Several population based screening studies have shown
that screening reduces AAA-related mortality.5e9
The large randomizedMulticentreAneurysmScreening
Study (MASS) recently published their 7-year follow-up
results, and found that the observed early mortality
benefit of screening for AAA was maintained in the
long term.3 A reduction in AAA-related mortality was
evident even after 15 years after a single US scan in
the final report from the randomizedChichester screen-
ing study.51
There are few clinical studies with a health eco-
nomic approach to the screening problem. In three
studies an economical analysis was added to the real
outcome.5,7,52 In the MASS the cost per life year gained
(LYG) was calculated to V 42 000 after four-years
follow-up, V 14 500 after 7-year follow-up and was
extrapolated to V 12 000 per LYG after 10 years.3,52
Lindholt et al.53 calculated the costs to be V 9 000 per
LYG after five years with an expected decrease
V 1 800 after 15 years.
In a Markov simulation cohort model we evaluated
various screening models and the cost per LYG when
screening 65 year old males once was V 8 000. There
was a trade-off between high prevalence of AAA
and lower life expectancey, eliminating the expected
benefits of screening high-risk groups such as smokers
or claudicants.50 A lower prevalence of AAA among
women was balanced by a higher rupture rate in the
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16 D. Bergqvist et al.model, making a screening programme of women
equally cost-effective.54
Although the studies show some variations in
monetary terms, still the cost per LYG seems reason-
able compared to many other accepted costs in the
health care sector, and well within what is generally
considered reasonable in society.55
Published cost-effectiveness analyses are all based
on OR, while any possible impact of EVAR has not
yet been evaluated. In short term, aneurysm related
death rate appears to be significantly lower for
EVAR, as a result of lower initial perioperative mortal-
ity rate.56 EVARmay also be an option for those consid-
ered unfit for open surgery, and may thereby reduce
the AAA-related mortality and increase the efficiency
of screening. However, although ICU and total hospi-
tal stay is significantly shorter for EVAR, this saving
is lost by the additional cost for EVAR device. Consid-
ering the unkown cost of postoperative surveillance,
the higher secondary intervention rate and the lack of
long-term outcome data, it is currently difficult to eval-
uate the impact of EVAR on cost-effectiveness.
No clinical studies have assessed the cost-utility of
screening for AAA, ie adjusting for quality of life.
Assuming general population utility57 in our Markov
model resulted in a cost per quality of life adjusted
year (QUALY) gained of V 10 300, whereas a hypo-
thetical reduction in utility among patients with
a screening-detected AAA, due to worries, would
reduce cost-effectiveness significantly.50
(10) The treatment of the disease should favour
the prognosis of the patients
The overall mortality in rupture is very high, still
around 80%,58 and presymptomatic elective repair in
appropriately selected individuals will prevent rup-
ture and thereby improve life expectancy. The long
term survival after successful elective repair is only
slightly shorter than that of an age-matched general
population.50 The price of elective surgery is a certain
postoperative morbidity and mortality. As stated
above the contemporary mortality is low, in Sweden
around 3%.26 The number needed to treat (NNT)
has been calculated to be three, i.e. three elective
AAA repairs need to be done to prevent one AAA
related death.7,50
Besides a reduction in AAA-related mortality, there
also seems to be a possible reduction in deaths from is-
chemic heart disease among the subjects screened.3 By
adopting a cardiovascular risk reduction programme
among patients with small screening detected AAA
this effect may be further enhanced, and perhaps
Eur J Vasc Endovasc Surg Vol 35, January 2008becomes as important, in terms of life years saved, as
the prophylactic AAA-repairs.
One concern, hitherto not sufficiently evaluated, is
how screening influences the quality of life (QoL) of
individuals getting the diagnosis AAA. Both the
knowledge of having an AAA and surgery for AAA
may have significant effects on QoL. With no screen-
ing about 30% of persons with an undetected AAA
at 65 years will eventually suffer from rupture or
have surgical repair of the aneurysm.50,59 Thus, ap-
proximately 70% will be free from rupture or surgery
and be ‘‘happily’’ unaware of the disease. With
screening the corresponding proportion would be
somewhat lower, approximately 60%,16 with a condi-
tion not requiring treatment but where the knowledge
may constitute a permanent source of anxiety. There-
fore, not only changes in survival, but also changes in
QoL have to be assessed. Data indicate that people
with a previously impaired quality of life will be neg-
atively influenced mentally by they having an AAA
diagnosed.60
Conclusion and Remaining Questions
AAA fulfils the WHO criteria for a disease suitable for
screening to be undertaken. This is, however, only
true for elderly men. A suitable age in the male pop-
ulation when screening should be considered seems
to be somewhere around 65 years. However, the opti-
mal age has not yet been established. Whether women
or other specific high risk groups would benefit from
screening has not been sufficiently evaluated.
Although current knowledge on the natural course
of AAA is sufficient to fulfil the WHO criteria, several
important aspects need further research. The most im-
portant are the pathophysiological processes behind
expansion and rupture. With increased knowledge
of these factors, therapeutic options for small AAA
may be available in the future. The possible impact
of secondary prevention measures among patients
with screening detected AAA, such as smoking cessa-
tion has to be evaluated.
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